The results of cardiovascular outcome trials (CVOTs) in people with type 2 diabetes mellitus and increased cardiovascular risk have demonstrated a significant benefit in terms of reduction in time to first major adverse cardiovascular event (MACE) with the use of liraglutide, semaglutide, albiglutide and dulaglutide [15]
Ready to explore whether GLP-1 treatmentoral or injectableis right for you
This is normal and does not indicate the peptide has stopped working
1 Environmental or metabolic stressors, including nutritional state, physical activity, hormonal regulation, and pathological conditions such as heart failure, cancer cachexia, and chronic liver disease, require appropriate fuel selection to maintain metabolic homeostasis
This is not quite the whole story